X
Pharma Advancement
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    Avadel Pharmaceuticals Receives

    Avadel Pharmaceuticals Receives Orphan Drug Designation from FDA for LUMRYZ™ (sodium oxybate) for Extended-Release Oral Suspension for the Treatment of Idiopathic Hypersomnia

    Robots and AI in Drug

    Robots and AI in Drug Discovery Are Transforming Medicine

    Stringent Policy around COVID Vaccines Laid by FDA

    Stringent Policy around COVID Vaccines Laid by FDA

    Pharmaceutical-Chemicals Market Booms with Rising API Demand

    Pharmaceutical Chemicals Market Booms with Rising API Demand

    Next in Pharma 2025 Innovations

    Next in Pharma 2025: Innovations Shaping the Future

    Work Smart: Go for Hands-Free Lab Informatics at the Bench, Not Scribbled Notes and Delayed Documentation at Your Desk

    Clinical Development

    AI Revolutionizing Drug Discovery and Clinical Development

    Drug-Development

    China’s Super Me-Too Drug Development: A New Pharma Frontier

    Omics Based Clinical Trials

    Asia Pacific Omics-Based Clinical Trials Market Growth

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    Avadel Pharmaceuticals Receives

    Avadel Pharmaceuticals Receives Orphan Drug Designation from FDA for LUMRYZ™ (sodium oxybate) for Extended-Release Oral Suspension for the Treatment of Idiopathic Hypersomnia

    Robots and AI in Drug

    Robots and AI in Drug Discovery Are Transforming Medicine

    Stringent Policy around COVID Vaccines Laid by FDA

    Stringent Policy around COVID Vaccines Laid by FDA

    Pharmaceutical-Chemicals Market Booms with Rising API Demand

    Pharmaceutical Chemicals Market Booms with Rising API Demand

    Next in Pharma 2025 Innovations

    Next in Pharma 2025: Innovations Shaping the Future

    Work Smart: Go for Hands-Free Lab Informatics at the Bench, Not Scribbled Notes and Delayed Documentation at Your Desk

    Clinical Development

    AI Revolutionizing Drug Discovery and Clinical Development

    Drug-Development

    China’s Super Me-Too Drug Development: A New Pharma Frontier

    Omics Based Clinical Trials

    Asia Pacific Omics-Based Clinical Trials Market Growth

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home News

Water Unit of DuPont Has Some Potential Buyers Interested

Content Team by Content Team
27th June 2024
in News
Water Unit of DuPont Has Some Potential Buyers Interested

The water treatment business of DuPont De Nemours Inc., which the US chemicals group happens to be planning to spin out, happens to be drawing a separate interest in a takeover from certain potential and probable industry buyers.

It is well to be noted that Veralto Corp. and Xylem Inc. happen to be among the probable suitors that happen to be in the early stages of assessing DuPont Water Solutions business.

Interestingly, in May 2024, DuPont said that it is going to be separating its electronics as well as water units by way of tax-free transactions, and the process is anticipated to be finished in a couple of years, thereby creating a trio of publicly traded businesses. Notably, the water business of DuPont may get a valuation of around $6 billion or even more, which also includes debt in any sale.

DuPont shares saw a rise of almost 3.1% on June 24, with the stock being up 1.8% in New York at around 3.21 p.m., thereby giving the company a market value of almost $34 billion.

There are deliberations that are ongoing, and there is indeed a level of uncertainty that Xylem or Veralto are going to decide to go behind any offers for the asset from DuPont. In one of the investor update calls in May 2024, Edward Breen, DuPont’s chairman, went on to confirm that the company wasn’t going ahead and running a formal M&A process when it came to the water unit.

It is interesting to note that DuPont Water Solutions happens to offer services that make the water safe to drink and, at the same time, works with companies throughout a range of sectors on making their usage of water more sustainable as well as efficient. The business went on to generate revenue of almost $1.5 billion in 2023, as per the annual report of the company, which, by the way, was broadly flat in 2022.

So as to split itself up. DuPont happens to add its name to an enlarged list of industrial conglomerates such as J&J, GE, thereby looking to boost returns by breaking into much smaller and more focused businesses. Significantly, DuPont has already gone on to spin out major business lines since the time its merger with Dow Chemical took place almost ten years back.

Previous Post

The Fauna Pharmaceutical Pollution: Scientists Sound Alarm

Next Post

Innovative Strategies For A Greener Pharmaceutical Sector

Related Posts

SCHOTT Pharma Invests
News

SCHOTT Pharma Invests EUR 100 Million in RTU Cartridges

9th June 2025
Stringent Policy around COVID Vaccines Laid by FDA
FDA Approvals

Stringent Policy around COVID Vaccines Laid by FDA

29th May 2025
Drugmakers Asked to Strictly Follow the US Pricing Reforms
Manufacturing

Drugmakers Asked to Strictly Follow the US Pricing Reforms

28th May 2025
DHL Supply Chain
News

DHL Supply Chain comes up with New Pharma Hub in Singapore

19th April 2025
Healthcare Packaging
Asia

Amcor Healthcare Packaging Expansion in Asia Pacific

16th April 2025
Drug Development

Advanced Instruments All Set To Merge With Nova Biomedical

22nd March 2025
Next Post
Sirio Europe invest in advanced manufacturing and green technologies at Brandenburg site

Innovative Strategies For A Greener Pharmaceutical Sector

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Subscribe Us

System

  • Search
  • Sitemap
  • RSS Feed

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack
  • Newsletters Archive

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Articles
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In